U.S. Markets open in 3 hrs 3 mins

Johnson & Johnson’s Erleada Approved by Health Canada

Sarah Collins
Johnson & Johnson’s Erleada Approved by Health Canada

On July 4, Johnson & Johnson’s (JNJ) pharmaceuticals division, Janssen, received Health Canada’s approval for its drug Erleada (apalutamide), which is used for the treatment of patients with nmCRPC (nonmetastatic castration-resistant prostate cancer). Erleada is the first treatment available for men with nmCRPC, which is referred to as a condition characterized by continued disease progression despite undergoing ADT (androgen deprivation therapy). It’s administered to patients in whom the disease has not spread to other parts of the body.